{ "entity_id": "B-003292", "folder": "National-Immunoglobulin-Governance-Advisory-Committee", "name": "National Immunoglobulin Governance Advisory Committee", "type": "Ministerial Council", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees", "data_status": "rich", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": true, "has_kpi_results": true, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_global_initiatives_structured": false, "n_global_initiatives": 0, "has_ideas": true, "has_artifacts": true, "n_ideas": 10, "n_legislation": 0, "n_artifacts": 4, "n_kpi_targets": 2, "n_kpi_results": 2, "n_outcomes": 1, "verified_own_data": true }, "strategy_profile": { "status": "published", "confidence": "high", "summary": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "official_site_url": "https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees", "source_documents": [ { "type": "annual_report", "title": "Annual Report", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "period": "2025", "confidence": "high" }, { "type": "corporate_plan", "title": "Corporate Plan", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "period": "2025", "confidence": "high" } ], "purpose": { "text": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 2, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=2" }, "vision": null, "strategic_priorities": [ { "title": "Provide advice and make recommendations to the NBA to support the Program", "description": "Provide advice and make recommendations to the NBA to support the Program", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" }, { "title": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and ", "description": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" }, { "title": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governa", "description": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products.", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" } ], "values": [ { "name": "Behave honestly and with integrity", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Treat everyone with respect and courtesy", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Act with care and diligence", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Comply with all applicable Australian laws", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Maintain appropriate confidentiality", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Disclose, and take reasonable steps to avoid, any conflict of interest", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Use Commonwealth resources in a proper manner", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Do not disclose or make improper use of inside information", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null } ], "outcomes": [ { "name": "Outcome 1: Governance and management of immunoglobulin products", "description": "The Program aims to ensure product use and management reflects appropriate clinical practice, represents efficient, effective and ethical expenditure of government funds, is in accordance with relevant national safety and quality standards for health care, and ensures that access to Ig products is consistent with the criteria for access determined by Governments.", "activities": [ "Development and maintenance of policies and procedures for access to Ig products", "Establishment and support of a national network of committees", "Evolving the criteria for access", "Development and implementation of a national ordering and outcomes database", "Improving performance", "Facilitating knowledge development", "Potential efficiency improvements" ], "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 8, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=8" } ], "performance_measures": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "target": "Feasible and appropriate", "latest_result": "N/A", "status": "Not achieved", "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "target_source_page": 9, "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "result_source_page": null }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "target": "N/A", "latest_result": "N/A", "status": "Not achieved", "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "target_source_page": 9, "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "result_source_page": null } ], "document_alignment_terms": { "must_support": [ "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the Nat", "Provide advice and make recommendations to the NBA to support the Program", "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products." ], "watch_terms": [ "Automated authorisation of access to Ig products", "Improved efficiency through streamlined product distribution" ], "avoid_claiming_without_evidence": [] }, "review_note": "" }, "global_initiatives": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "purposes_source_page": 2, "how_we_deliver": "The Program is delivered through a package of measures which implements an integrated national framework for governance and management of immunoglobulin products.", "how_we_deliver_source_page": 7, "government_priorities": [ { "text": "Provide advice and make recommendations to the NBA to support the Program", "source_page": 7 }, { "text": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "source_page": 7 }, { "text": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products.", "source_page": 7 } ], "outcomes": [ { "name": "Outcome 1: Governance and management of immunoglobulin products", "description": "The Program aims to ensure product use and management reflects appropriate clinical practice, represents efficient, effective and ethical expenditure of government funds, is in accordance with relevant national safety and quality standards for health care, and ensures that access to Ig products is consistent with the criteria for access determined by Governments.", "key_activities": [ "Development and maintenance of policies and procedures for access to Ig products", "Establishment and support of a national network of committees", "Evolving the criteria for access", "Development and implementation of a national ordering and outcomes database", "Improving performance", "Facilitating knowledge development", "Potential efficiency improvements" ], "source_page": 8 } ], "values": [ "Behave honestly and with integrity", "Treat everyone with respect and courtesy", "Act with care and diligence", "Comply with all applicable Australian laws", "Maintain appropriate confidentiality", "Disclose, and take reasonable steps to avoid, any conflict of interest", "Use Commonwealth resources in a proper manner", "Do not disclose or make improper use of inside information" ], "values_framework_name": "Australian Public Service (APS) Code of Conduct", "kpi_targets_2025_26": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "target": "Feasible and appropriate", "source_page": 9 }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "target": "N/A", "source_page": 9 } ], "kpi_results_2024_25": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "result": "N/A", "status": "Not achieved", "source_page": null }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "result": "N/A", "status": "Not achieved", "source_page": null } ], "_source_urls": { "annual_report_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "corporate_plan_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf" } }, "ideas": [ { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "The following, adapted from the Australian Public Service (APS) Code of Conduct, as set out in s 13\nof the PS Act, outline the conduct expectations of members:\n• Behave honestly and with integrity in the course of official activities\n• Treat everyone with respect and courtesy, and without harassment\n• Act with care and diligence\n• Comply with all applicable Australian laws\n• Maintain appropriate confidentiality\n• Disclose, and take reasonable steps to avoid, any conflict of interest (real or apparent)\n• Use Commonwealth resources in a proper manner\n• Do not disclose or make improper use of inside information\n• At all times behave in a way that upholds the integrity and good reputation of the NBA and\nthe Commonwealth.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "The following, adapted from the Australian Public Service (APS) Code of Conduct, as set out in s 13\nof the PS Act, outline the conduct expectations of members:\n• Behave honestly and with integrity in the course of official activities\n• Treat everyone with respect and courtesy, and without harassment\n• Act with care and diligence\n• Comply with all applicable Australian laws\n• Maintain appropriate confidentiality\n• Disclose, and take reasonable steps to avoid, any conflict of interest (real or apparent)\n• Use Commonwealth resources in a proper manner\n• Do not disclose or make improper use of inside information\n• At all times behave in a way that upholds the integrity and good reputation of the NBA and\nthe Commonwealth.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[Page 8]\nOFFICIAL\nThe specific implementation arrangements may vary according to the circumstances of different\njurisdictions or health services, within the objective of ensuring nationally consistent Ig governance\nand management outcomes.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[Page 8]\nOFFICIAL\nThe specific implementation arrangements may vary according to the circumstances of different\njurisdictions or health services, within the objective of ensuring nationally consistent Ig governance\nand management outcomes.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "Medical Specialty Representatives*: NBA to appoint members based on\nEach SWG must have a minimum of 5 members consultation with Jurisdictional government\nand include: health departments and other relevant\n– Representation from both adult and stakeholders.\npaediatric specialities (where relevant) Each relevant SWG will include at least 1\n– Members from at least 4 jurisdictions representative from the relevant society:\n*Persons with clinical expertise and appropriate – Neurology Group - Australian and New\nqualifications to consider the clinical Zealand Association of\nappropriateness, safety and cost effectiveness of Neurologists(ANZAN)\nIg, including comparative outcomes of different – Haematology Group - Haematology Society\ntherapies. of Australia and New Zealand (HSANZ)\n– Immunology Group - Australasian Society\nof Clinical Immunology and Allergy (ASCIA)", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "Medical Specialty Representatives*: NBA to appoint members based on\nEach SWG must have a minimum of 5 members consultation with Jurisdictional government\nand include: health departments and other relevant\n– Representation from both adult and stakeholders.\npaediatric specialities (where relevant) Each relevant SWG will include at least 1\n– Members from at least 4 jurisdictions representative from the relevant society:\n*Persons with clinical expertise and appropriate – Neurology Group - Australian and New\nqualifications to consider the clinical Zealand Association of\nappropriateness, safety and cost effectiveness of Neurologists(ANZAN)\nIg, including comparative outcomes of different – Haematology Group - Haematology Society\ntherapies. of Australia and New Zealand (HSANZ)\n– Immunology Group - Australasian Society\nof Clinical Immunology and Allergy (ASCIA)", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "Clinical Associate Professor, Department of Medicine, University of Adelaide\nMedical specialist – neurology\nAssociate Professor Stephen Reddel, Staff Specialist Neurologist, Concord Repatriation General Hospital, New South Wales\nMedical specialist – transplant medicine\nAssociate Professor Ross Francis\n,\nSenior Staff Specialist - Kidney Medicine/Kidney Transplantation, Princess Alexandra Hospital, Brisbane, Queensland\nConsumer representatives (2)\nDr Lisa Wright, Myasenthia Alliance Australia (MAA) board member; committee member of Myasenthia Gravis Association of Queensland (MGAQ)\nMs Jackie Murphy,\nPresident, Australian Primary Immune Deficiency Patient Support (AusPIPS)\nDispenser representative\nMs Kylie Fitch, Assistant Manager, Sullivans Nicolaides Pathology, Corporate Blood Bank, Bowen Hills, Queensland\nEpidemiologist", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "Clinical Associate Professor, Department of Medicine, University of Adelaide\nMedical specialist – neurology\nAssociate Professor Stephen Reddel, Staff Specialist Neurologist, Concord Repatriation General Hospital, New South Wales\nMedical specialist – transplant medicine\nAssociate Professor Ross Francis\n,\nSenior Staff Specialist - Kidney Medicine/Kidney Transplantation, Princess Alexandra Hospital, Brisbane, Queensland\nConsumer representatives (2)\nDr Lisa Wright, Myasenthia Alliance Australia (MAA) board member; committee member of Myasenthia Gravis Association of Queensland (MGAQ)\nMs Jackie Murphy,\nPresident, Australian Primary Immune Deficiency Patient Support (AusPIPS)\nDispenser representative\nMs Kylie Fitch, Assistant Manager, Sullivans Nicolaides Pathology, Corporate Blood Bank, Bowen Hills, Queensland\nEpidemiologist", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] } ], "legislation_administered": [], "artifacts": [ { "category": "other-pdfs", "year": "2026", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf", "file": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf", "bytes": 397687, "link_text": "National Immunoglobulin Governance Advisory Committee (NIGAC) - Terms of Reference - February 2026.pdf" }, { "category": "other-pdfs", "year": "2024", "url": "https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf", "file": "other-pdfs/SWG-20terms-20of-20reference.pdf", "bytes": 224329, "link_text": "SWG terms of reference.pdf" }, { "category": "annual-reports", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "file": "annual-reports/2025.pdf", "bytes": 3522745, "link_text": "Annual Report" }, { "category": "corporate-plans", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "file": "corporate-plans/2025.pdf", "bytes": 6435684, "link_text": "Corporate Plan" } ], "_meta": { "snapshot_built_at": "2026-05-14T02:13:19+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "National-Immunoglobulin-Governance-Advisory-Committee", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "other-pdfs\\National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.txt", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf", "year": null }, "usage": { "input_tokens": 5618, "output_tokens": 861, "total_tokens": 6479, "model": "nova-micro" }, "cost_usd": 0.00031717000000000003, "elapsed_seconds": 2.88, "generated_at": "2026-05-13T10:33:36+00:00" }, "ideas_manifest": { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "generated_at": "2026-05-09T23:05:41.551856+00:00", "idea_count": 10, "markdown": "ideas/National-Immunoglobulin-Governance-Advisory-Committee_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "National-Immunoglobulin-Governance-Advisory-Committee_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }